Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Give their signed written informed consent to participate~2. At least 40 years of age and no older than 80 years of age~3. COPD patients who are symptomatic~4. Must be receiving one or more inhaled bronchodilators as maintenance therapy~5. Must have a documented history of COPD exacerbations~Exclusion Criteria:~1. Current diagnosis of asthma~2. COPD due to α1-Antitrypsin Deficiency~3. Known active tuberculosis, lung cancer, cystic fibrosis, and significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months.~4. Long-term-oxygen therapy (≥ 15 hours a day).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BFF MDI (PT009) 320/9.6 μg (Type: EXPERIMENTAL): Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
- BFF MDI (PT009) 160/9.6 μg (Type: EXPERIMENTAL): Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
- FF MDI (PT005) 9.6 μg (Type: EXPERIMENTAL): Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID

Based on this trial design, predict the completion outcome and termination type (if applicable).